Last reviewed · How we verify
NCT05496933
Colombia National Porphyria Registry
trial in Rare Diseases in 100 participants. Status unknown.
21 December 2021
Quick facts
| Lead sponsor | Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 April 2021 |
| Primary completion | 21 December 2021 |
| Estimated completion | 30 December 2022 |
| Sites | 1 location across Colombia |
Conditions studied
- Rare Diseases — all drugs for Rare Diseases →
- Porphyrias — all drugs for Porphyrias →
Sponsor
Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia
Who can join
Eligibility, any sex, with Rare Diseases or Porphyrias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
porphyria is classified as a rare disease and is produced by defects in the enzymatic activity in the biosynthesis of the heme group that leads to the over-accumulation and excretion of porphyrin precursors in hepatocytes or erythroid cells, extrahepatic or extramedullary cells, tissue, and end-organ injury. Acute intermittent porphyria is the most common and severe form of hepatic porphyria, with an annual incidence of symptomatic patients of 0.13 per million people. Aim: characterization of cases of acute hepatic porphyria in Colombia. Methods: a descriptive pilot study of patients diagnosed with acute hepatic porphyria's in Colombia. Patients of all age groups with a confirmed diagnosis of acute hepatic porphyria. Patients with concomitant pathologies, as well as pregnant women, will also be included. Patients who refuse to participate in the study will be excluded. Expected results: describe the sociodemographic and clinical characteristics of patients with a diagnosis of acute hepatic porphyria, and encourage patients and/or representatives in the research agenda.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05496933
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rare Diseases
Currently open trials in the same condition.
- NCT06595940 — Genetic Analysis of Uncommon Disease Presentations in Non-US Populations · recruiting
- NCT07247279 — Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia · recruiting
- NCT07102966 — Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas · NA · recruiting
- NCT06856902 — BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe · NA · recruiting
- NCT06926127 — Genomic Profiling of Genetic and Rare Diseases · NA · recruiting
Other Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia trials
Trials by the same sponsor.
- NCT03580941 — Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy · unknown
- NCT03574506 — Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series · unknown
- NCT04621539 — Validation of the Quick Sequential [Sepsis-related] Organ Failure Assessment (qSOFA) in Obstetric Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05496933 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia
- Last refreshed: 1 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05496933.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing